Eurostars project, MTP in situ sequencer, 9877,
|OLINK BIOSCIENCE AB
|Funding from Vinnova
|SEK 7 772
|October 2015 - October 2017
Purpose and goal
Together with SU, Olink Bioscience engages in development of in situ sequencing assays that can be used i. a. on the MTP in situ sequencer developed in this project.
Expected results and effects
Spatially resolved multiplexed profiling of biomarkers is expected to improve our understanding of highly heterogenous tissues such as brain as well as shedding light on the biology of complex diseases including cancer. Full automation of in situ sequencing assays is expected to make this spatial profiling technology more accessible to researchers and clinicians who might use in situ sequencing as a diagnostic tool in the future, similar to how simple histological and immunochemical stains are used today.
Planned approach and implementation
Olink Bioscience has scheduled regular meetings with SU to provide their expertise in development of commercial assays including assay validation and the implementation of quality control routines.